Sarepta Therapeutics Inc (SRPT)

概要ニュース株価時系列オプションチェーン Financials なぜSRPTが下落しているのか？ディスカッション予測株式分割

なぜSarepta Therapeutics Inc（SRPT）の株価が下がっていますか？

2026-04-08 の取引セッション中に、Sarepta Therapeutics Inc (SRPT) 株の 5.11% 下落を確認しました。これは通常のボラティリティやさまざまな内部および外部要因に起因する可能性がありますが、当社では状況を積極的に監視しており、できるだけ早くタイムリーな最新情報を提供することに注意してください。

2023-06-23:

SRPT's stock fell 7.93% as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enough to secure approval for expanded use.

https://www.reuters.com/business/healthcare-pharmaceuticals/sarepta-slumps-concerns-emerge-around-upcoming-gene-therapy-data-2023-06-23/

2023-04-13:

Before the market opened on Thursday, shares of Sarepta Therapeutics (NASDAQ: SRPT) experienced a decline of roughly 10% in pre-market trading. This drop occurred following a report stating that the U.S. Food and Drug Administration (FDA) staff had a leaning towards rejecting the company's Duchenne muscular dystrophy gene therapy, but a senior official intervened.

https://www.investing.com/news/stock-market-news/sarepta-tumbles-10-on-report-fda-leaned-toward-rejecting-duchenne-therapy-432SI-3054655

2023-03-17:

Sarepta Therapeutics's stock is going down today after the announcement of an advisory meeting for the SRP-9001's development (the first gene therapy) with the FDA, since their gene therapy isn't believed to be beneficial. The meeting comes as the company was preparing for the SRP-9001 regulatory action date on May 29, 2023.